179 related articles for article (PubMed ID: 30936122)
1. Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.
Colomban O; Tod M; Leary A; Ray-Coquard I; Lortholary A; Hardy-Bessard AC; Pfisterer J; Du Bois A; Kurzeder C; Burges A; Péron J; Freyer G; You B
Clin Cancer Res; 2019 Sep; 25(17):5342-5350. PubMed ID: 30936122
[TBL] [Abstract][Full Text] [Related]
2. The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study).
You B; Colomban O; Heywood M; Lee C; Davy M; Reed N; Pignata S; Varsellona N; Emons G; Rehman K; Steffensen KD; Reinthaller A; Pujade-Lauraine E; Oza A
Gynecol Oncol; 2013 Aug; 130(2):289-94. PubMed ID: 23694718
[TBL] [Abstract][Full Text] [Related]
3. CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
You B; Robelin P; Tod M; Louvet C; Lotz JP; Abadie-Lacourtoisie S; Fabbro M; Desauw C; Bonichon-Lamichhane N; Kurtz JE; Follana P; Leheurteur M; Piano FD; Ferron G; De Rauglaudre G; Ray-Coquard I; Combe P; Chevalier-Place A; Joly F; Leary A; Pujade-Lauraine E; Freyer G; Colomban O
Clin Cancer Res; 2020 Sep; 26(17):4625-4632. PubMed ID: 32209570
[TBL] [Abstract][Full Text] [Related]
4. Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".
van Wagensveld L; Colomban O; van der Aa MA; Freyer G; Sonke GS; Kruitwagen RFPM; You B
J Gynecol Oncol; 2024 May; 35(3):e34. PubMed ID: 38216134
[TBL] [Abstract][Full Text] [Related]
5. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
You B; Purdy C; Copeland LJ; Swisher EM; Bookman MA; Fleming G; Coleman R; Randall LM; Tewari KS; Monk BJ; Mannel RS; Walker JL; Cappuccini F; Cohn D; Muzaffar M; Mutch D; Wahner-Hendrickson A; Martin L; Colomban O; Burger RA
J Clin Oncol; 2022 Dec; 40(34):3965-3974. PubMed ID: 36252167
[TBL] [Abstract][Full Text] [Related]
6. CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals.
Li C; Cui Q; Wang X; Yao S; Tu H; Chen M
BMC Cancer; 2024 May; 24(1):609. PubMed ID: 38769484
[TBL] [Abstract][Full Text] [Related]
7. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
[TBL] [Abstract][Full Text] [Related]
8. Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
Corbaux P; You B; Glasspool RM; Yanaihara N; Tinker AV; Lindemann K; Ray-Coquard IL; Mirza MR; Subtil F; Colomban O; Péron J; Karamouza E; McNeish I; Kelly C; Kagimura T; Welch S; Lewsley LA; Paoletti X; Cook A
Eur J Cancer; 2023 Sep; 191():112966. PubMed ID: 37542936
[TBL] [Abstract][Full Text] [Related]
9. Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.
Ferrandina G; Ludovisi M; Corrado G; Carone V; Petrillo M; Scambia G
Gynecol Oncol; 2008 May; 109(2):187-93. PubMed ID: 18343487
[TBL] [Abstract][Full Text] [Related]
10. Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10.
Colomban O; Swisher EM; Kristeleit R; McNeish I; Shapira-Frommer R; Goble S; Lin KK; Maloney L; Freyer G; You B
EBioMedicine; 2023 Mar; 89():104477. PubMed ID: 36801617
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients.
Bouvarel B; Colomban O; Frenel JS; Loaec C; Bourgin C; Berton D; Freyer G; You B; Classe JM
Int J Gynecol Cancer; 2024 Apr; 34(4):574-580. PubMed ID: 38242546
[TBL] [Abstract][Full Text] [Related]
12. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of CA125 kinetics, half-life, and nadir in the treatment of epithelial ovarian cancer: a systematic review and meta-analysis.
Kim JH; Cho HW; Park EY; Han KH; Kim ET; Lee JK; Park SY; Armbrust R; Fotopoulou C; Lim MC
Int J Gynecol Cancer; 2023 Dec; 33(12):1913-1920. PubMed ID: 37949486
[TBL] [Abstract][Full Text] [Related]
14. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer.
Kus F; Guven DC; Yildirim HC; Chalabiyev E; Akyildiz A; Tatar OD; Sahin YB; Ileri S; Karaca E; Kertmen N; Arik Z
Biomark Med; 2023 Apr; 17(7):379-389. PubMed ID: 37309756
[TBL] [Abstract][Full Text] [Related]
15. Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development.
Wilbaux M; Hénin E; Oza A; Colomban O; Pujade-Lauraine E; Freyer G; Tod M; You B
Gynecol Oncol; 2014 Jun; 133(3):460-6. PubMed ID: 24726614
[TBL] [Abstract][Full Text] [Related]
16. Management of platinum-sensitive recurrent ovarian cancer.
Pfisterer J; Ledermann JA
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S12-6. PubMed ID: 16716798
[TBL] [Abstract][Full Text] [Related]
17. CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
You B; Sehgal V; Hosmane B; Huang X; Ansell PJ; Dinh MH; Bell-McGuinn K; Luo X; Fleming GF; Friedlander M; Bookman MA; Moore KN; Steffensen KD; Coleman RL; Swisher EM
J Clin Oncol; 2023 Jan; 41(1):107-116. PubMed ID: 35867965
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Oza AM; Matulonis UA; Alvarez Secord A; Nemunaitis J; Roman LD; Blagden SP; Banerjee S; McGuire WP; Ghamande S; Birrer MJ; Fleming GF; Markham MJ; Hirte HW; Provencher DM; Basu B; Kristeleit R; Armstrong DK; Schwartz B; Braly P; Hall GD; Nephew KP; Jueliger S; Oganesian A; Naim S; Hao Y; Keer H; Azab M; Matei D
Clin Cancer Res; 2020 Mar; 26(5):1009-1016. PubMed ID: 31831561
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.
Levy T; Weiser R; Boaz M; Shem EB; Golan A; Menczer J
Int J Gynecol Cancer; 2012 Oct; 22(8):1344-8. PubMed ID: 22954785
[TBL] [Abstract][Full Text] [Related]
20. Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial.
Colomban O; Clamp A; Cook A; McNeish IA; You B
JCO Clin Cancer Inform; 2023 Apr; 7():e2200188. PubMed ID: 37075255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
